Private Advisor Group LLC Purchases 4,010 Shares of Gilead Sciences, Inc. $GILD

Private Advisor Group LLC raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.7% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 50,035 shares of the biopharmaceutical company’s stock after purchasing an additional 4,010 shares during the quarter. Private Advisor Group LLC’s holdings in Gilead Sciences were worth $6,973,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Strategic Investment Solutions Inc. IL purchased a new stake in Gilead Sciences during the fourth quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC grew its position in shares of Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 85 shares during the period. Quattro Advisors LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter worth $26,000. Wealth Preservation Advisors LLC increased its stake in shares of Gilead Sciences by 60.0% in the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 81 shares in the last quarter. Finally, Ares Financial Consulting LLC bought a new position in Gilead Sciences in the 4th quarter worth $28,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the subject of several recent research reports. Citigroup boosted their price target on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a report on Monday, April 13th. Leerink Partners decreased their price objective on Gilead Sciences from $148.00 to $146.00 in a research note on Friday, May 8th. HSBC raised Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price objective for the company from $133.00 to $155.00 in a research report on Monday. Weiss Ratings lowered shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, May 28th. Finally, Morgan Stanley decreased their target price on shares of Gilead Sciences from $175.00 to $168.00 in a research note on Friday, May 8th. Twenty-six research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $159.19.

Gilead Sciences Price Performance

NASDAQ:GILD traded up $5.05 on Tuesday, reaching $134.66. 1,629,010 shares of the company’s stock traded hands, compared to its average volume of 7,190,654. The stock has a 50-day simple moving average of $129.44 and a 200-day simple moving average of $134.64. Gilead Sciences, Inc. has a 12 month low of $107.75 and a 12 month high of $157.29. The firm has a market cap of $167.19 billion, a PE ratio of 18.34 and a beta of 0.32. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm’s revenue was up 4.4% on a year-over-year basis. During the same quarter last year, the business posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post -0.8 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend was Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the sale, the chief financial officer owned 171,646 shares in the company, valued at $21,524,408.40. This trade represents a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $126.29, for a total transaction of $1,894,350.00. Following the completion of the transaction, the chief executive officer directly owned 607,133 shares in the company, valued at $76,674,826.57. This trade represents a 2.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 83,000 shares of company stock worth $10,824,500 over the last quarter. Insiders own 0.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.